Table 1 Multivariate analysis of factor affecting progression-free survival in the whole cohort.
From: Clinical and NGS predictors of response to regorafenib in recurrent glioblastoma
Covariate | Hazard ratio | Confidence interval | p-value |
|---|---|---|---|
MGMT | 0.535 | 0.170–1.683 | 0.2849 |
Extent of resection | 0.241 | 0.065–0.889 | 0.0326 |
EGFRvIII | 2.2556 | 0.666–9.814 | 0.1715 |
Age | 0.841 | 0.317–2.230 | 0.7274 |
MAPK pathway mutation | 5.485 | 1.325–22.703 | 0.0188 |
